09/18/23 7:05 AMNasdaq : VIRI low floatVirios Therapeutics Announces Termination of At-The-Market Sales AgreementVirios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases such as fibromyalgia and Long-COVID, today announced that itRHEA-AIneutral
09/12/23 7:05 AMNasdaq : VIRI conferenceslow floatVirios Therapeutics CEO Greg Duncan to Present at the SHARE™️ Series Investor Event on Monday, September 18, 2023Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases such as fibromyalgia (“FM”) and Long-COVID (“LC”), announced todayRHEA-AIneutral
08/14/23 7:05 AMNasdaq : VIRI low floatVirios Therapeutics Announces Halt to At-The-Market Offering SalesVirios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases such as fibromyalgia (“FM”) and Long-COVID, today announced that itRHEA-AIneutral
08/10/23 7:05 AMNasdaq : VIRI earningslow floatVirios Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate UpdateVirios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviralRHEA-AIneutral
08/09/23 7:05 AMNasdaq : VIRI clinical triallow floatVirios Therapeutics Announces Plans to Advance Lead Candidate IMC-1 to Phase 3 Development as a New Treatment Option for FibromyalgiaVirios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases such as fibromyalgia (“FM”) and Long-COVID, today announced that theRHEA-AIneutral
08/03/23 4:05 PMNasdaq : VIRI conferencesearningslow floatVirios Therapeutics to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID,RHEA-AIneutral
07/17/23 7:05 AMNasdaq : VIRI covid-19low floatVirios Therapeutics Announces Positive Data Demonstrating Improvement in Multiple Long-COVID Symptoms Following Treatment with a Combination of Valacyclovir and Celecoxib in an Exploratory, Open-Label, Proof of Concept StudyVirios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”), today announced that female patientsRHEA-AIneutral
05/25/23 4:05 PMNasdaq : VIRI low floatVirios Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementVirios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a clinical‐stage biopharmaceutical company, today announced that it has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market. Below are someRHEA-AIpositive
05/15/23 7:05 AMNasdaq : VIRI clinical triallow floatVirios Therapeutics Announces Submission of Final Toxicology Results to Support Proposed Phase 3 Program for Novel Therapy to Treat FibromyalgiaVirios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”), today announced that it has submittedRHEA-AIvery positive
05/11/23 7:05 AMNasdaq : VIRI earningslow floatVirios Therapeutics Announces First Quarter 2023 Financial ResultsVirios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”), today announced financial results forRHEA-AIneutral